Tirzepatide vs Semaglutide: What the Head-to-Head Trial Showed

Tirzepatide vs semaglutide is the most searched comparison in this field. Both are long-acting peptides used to study appetite, blood sugar and fat tissue, but they work through different receptors. Tirzepatide switches on two, GIP and GLP-1. Semaglutide switches on one, GLP-1.

That single difference shows up in the results. In the only head-to-head obesity trial, tirzepatide cut body weight by 20.2% and semaglutide by 13.7%. This guide covers why, the numbers side by side, and what to check before buying either one. Everything below is for research and laboratory use only.

Key Takeaways

• Tirzepatide is a dual agonist that switches on both the GIP and GLP-1 receptors, while semaglutide switches on only the GLP-1 receptor. Every other difference follows from this.
• In the head-to-head SURMOUNT-5 trial (NEJM, 2025), tirzepatide cut average body weight by 20.2% against 13.7% for semaglutide over 72 weeks, about 47% more.
• Their half-lives are close: about 5 days for tirzepatide and about 7 days (165 hours) for semaglutide. Both are given once a week in studies.
• Their molecules differ: tirzepatide is a 39-amino-acid peptide (about 4.8 kDa, CAS 2023788-19-2); semaglutide is a GLP-1 analogue (about 4113 Da, CAS 910463-68-2).
• Purity and verification matter more than the brand name. Both compounds must arrive with a published third-party HPLC COA confirming 99%+ purity before any research model is run.
• For the largest weight effect, tirzepatide leads. For a long-studied single-pathway baseline, semaglutide is still the reference.

Tirzepatide vs Semaglutide at a Glance

Most people want the numbers side by side before the mechanism. Here they are.

Tirzepatide gives the larger effect on body weight. Semaglutide has the longer research record as the first blockbuster GLP-1 drug. For the next generation, the three-receptor retatrutide, see the retatrutide vs tirzepatide vs semaglutide comparison.

The Mechanism: Dual GIP/GLP-1 vs Single GLP-1

The two behave differently because they bind different receptors.

Semaglutide switches on only the GLP-1 receptor. GLP-1 is a gut hormone that slows how fast the stomach empties, helps release insulin when blood sugar is high, and quiets the brain's hunger signals. Semaglutide is 94% the same as human GLP-1. One amino acid is swapped so the enzyme DPP-4 cannot cut it, and a C18 fatty acid lets it ride on albumin in the blood, so it lasts about a week.

Tirzepatide adds a second receptor, GIP (glucose-dependent insulinotropic polypeptide). It was built from the GIP chain, and it is described as an imbalanced dual agonist: it binds the GIP receptor about as strongly as natural GIP, but binds the GLP-1 receptor about five times more weakly than natural GLP-1 (Willard, 2020). The idea, backed by the trials, is that switching on both at once adds up to more effect on body weight, insulin and fat handling than one pathway alone (Coskun, 2018).

That two-receptor design is behind tirzepatide's larger effect. Both are available as kits: tirzepatide and semaglutide.

What the Head-to-Head Data Shows

The biggest change in this debate is that researchers no longer have to compare separate trials. SURMOUNT-5, a 72-week head-to-head study of 751 adults with obesity, ran both compounds in the same population (Aronne, 2025).

The result was clear. Tirzepatide cut average body weight by 20.2%, semaglutide by 13.7%: about 47% more for the dual agonist. People on tirzepatide were also more likely to reach losses of 10%, 15%, 20% and 25%.

The separate trials pointed the same way. In SURMOUNT-1, tirzepatide 15 mg cut 20.9% at 72 weeks (Jastreboff, 2022); in STEP 1, semaglutide 2.4 mg cut 14.9% at 68 weeks (Wilding, 2021). In type 2 diabetes, the SURPASS-2 trial found tirzepatide lowered blood sugar (HbA1c) more than semaglutide 1 mg (Frías, 2021).

One detail for tolerability research: in SURMOUNT-5, stopping because of stomach side effects was less common on tirzepatide (2.7%) than on semaglutide (5.6%), even though tirzepatide had the larger effect.

Half-Life, Stability, and Reconstitution

Both peptides are built to last in the body, which is why both are studied once a week.

Semaglutide lasts a little longer, about 165 hours (around 7 days), thanks to its DPP-4-resistant swap and strong albumin binding through a C18 fatty acid. Tirzepatide lasts about 5 days, using a C20 fatty acid that also binds albumin, slows clearance by the kidneys and shields it from DPP-4.

Both arrive as freeze-dried powder and are mixed with bacteriostatic water before use. Both are sensitive to heat and to repeated freezing and thawing. The guide on how to reconstitute research peptides and the peptide storage and stability guide cover the handling that protects either compound.

Purity and COA: The Factor That Outweighs the Comparison

Most comparisons miss this point: the mechanism does not matter if the vial does not hold what the label says. A 99% purity tirzepatide and a 99% purity semaglutide are both useless as research tools if the actual material is degraded, underdosed, or contaminated.

Every Lyze Labs batch of both compounds is third-party HPLC tested with a published Certificate of Analysis confirming 99%+ purity. Mass spectrometry confirms molecular identity against the expected molecular weight (~4.8 kDa for tirzepatide, ~4113 Da for semaglutide). Before you commit either peptide to a study, know how to read that paperwork. Our how to verify research peptide purity and COA guide walks through HPLC chromatograms line by line, and the research peptide scam red flags post lists the warning signs of suppliers who cannot back their claims.

Which Should You Choose for Your Research?

It depends on what your study asks.

Choose tirzepatide when your research is about the largest weight effect, how GIP and GLP-1 work together, or comparisons with the newest agonists. The head-to-head data gives it the larger effect, and its two-receptor design opens questions a single-pathway agonist cannot answer.

Choose semaglutide when you need the long-established single-pathway GLP-1 reference, a slightly longer half-life, or a baseline to measure dual and triple agonists against. As the first blockbuster GLP-1 analogue, it has the deepest published research.

Many labs buy both to run side-by-side arms. Whichever you select, the sourcing standard is identical: published third-party HPLC COA, confirmed 99%+ purity, and verified batch identity. Current batch documentation is on the tirzepatide and semaglutide kit pages.

Frequently Asked Questions

What is the main difference between tirzepatide vs semaglutide?

The receptors they switch on. Tirzepatide switches on both GIP and GLP-1 receptors, while semaglutide switches on only the GLP-1 receptor. The two-receptor design comes with a larger effect on body weight, including in the head-to-head SURMOUNT-5 trial.

Is tirzepatide or semaglutide more effective for weight loss in research?

Tirzepatide. In the head-to-head SURMOUNT-5 study (2025), it cut average body weight by 20.2% against 13.7% for semaglutide over 72 weeks, about 47% more. It has shown the larger effect on weight in every major comparison so far.

How do the half-lives of semaglutide vs tirzepatide compare?

Semaglutide lasts a little longer, about 165 hours (around 7 days), while tirzepatide lasts about 5 days. Both are given once a week in studies. Both last that long because a fatty acid binds them to albumin and a design change protects them from the enzyme DPP-4.

What are the CAS numbers and molecular weights for tirzepatide and semaglutide?

Tirzepatide has CAS number 2023788-19-2 and a molecular weight of about 4.8 kDa (4814 Da) across 39 amino acids. Semaglutide has CAS number 910463-68-2 and a molecular weight of about 4113 Da. Always confirm these identities against the mass spectrometry data on the Certificate of Analysis.

How do I verify purity when buying tirzepatide or semaglutide for research?

Require a published third-party HPLC Certificate of Analysis confirming 99%+ purity for the specific batch, plus mass spectrometry confirming molecular identity. Every Lyze Labs batch of both compounds ships with this documentation. Review our COA verification guide before sourcing either peptide to learn how to read the chromatograms.

Can I research tirzepatide and semaglutide side by side?

Yes. Many labs run side-by-side arms to compare dual-agonist and single-agonist effects under the same conditions, the cleanest way to repeat the SURMOUNT-5 design in your own model. Both compounds should meet the same sourcing standard of verified 99%+ purity and published batch COA.

Order Tirzepatide or Semaglutide for Your Research

Lyze Labs supplies both compounds at 99%+ HPLC-verified purity with a published COA, trusted by researchers in 150+ countries, with 10,000+ orders shipped. Each kit is ten vials from one batch. Shipping is free and tracked, most orders arrive in 7 to 14 days, and delivery is guaranteed. Order tirzepatide or semaglutide from the kit page; a person confirms your order and sends payment options, day or night.

Studies Cited

• Aronne LJ, et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine.
• Jastreboff AM, et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine.
• Wilding JPH, et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine.
• Frías JP, et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine.
• Willard FS, et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight.
• Coskun T, et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism.